GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Interest Coverage

Immunome (Immunome) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Immunome Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Immunome's Operating Income for the three months ended in Dec. 2023 was $-13.85 Mil. Immunome's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Immunome Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Immunome's Interest Coverage or its related term are showing as below:


IMNM's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 138.73
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Immunome Interest Coverage Historical Data

The historical data trend for Immunome's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Immunome Interest Coverage Chart

Immunome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - - N/A N/A

Immunome Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A No Debt No Debt N/A N/A

Competitive Comparison of Immunome's Interest Coverage

For the Biotechnology subindustry, Immunome's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunome's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Immunome's Interest Coverage falls into.



Immunome Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Immunome's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Immunome's Interest Expense was $0.00 Mil. Its Operating Income was $-28.73 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.34 Mil.

GuruFocus does not calculate Immunome's interest coverage with the available data.

Immunome's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Immunome's Interest Expense was $0.00 Mil. Its Operating Income was $-13.85 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.34 Mil.

GuruFocus does not calculate Immunome's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Immunome  (NAS:IMNM) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Immunome Interest Coverage Related Terms

Thank you for viewing the detailed overview of Immunome's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunome (Immunome) Business Description

Traded in Other Exchanges
N/A
Address
665 Stockton Drive, Suite 300, Exton, PA, USA, 19341
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.
Executives
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Robert Lechleider officer: Chief Medical Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett officer: SVP Operations C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Jack Higgins officer: Chief Scientific Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas director, other: See remarks 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner officer: Chief Strategy Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson officer: Chief Technology Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp director, 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast director
Michael Lefenfeld director IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma director, officer: President and CEO IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim director 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019